FDAnews Device Daily Bulletin

EnteroMedics' ReCharge Trial Demonstrates Statistically Significant Weight Loss in Obesity But Does Not Meet Predefined Efficacy Endpoints

Feb. 11, 2013
A A
EnteroMedics, the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, announced results from its randomized ReCharge Pivotal Trial of VBLOC vagal blocking therapy for the treatment of obesity.
Marketwatch